[Webinar recording] We welcome you to register for an exclusive media webinar, on: 'What do new research results mean for people with TB-HIV?' Get connected with noted experts from lead agencies such as the NIH Clinical Trial Site investigators (Chennai), International Union Against Tuberculosis and Lung Disease (The Union) and the World Health Organization (WHO)'s Global Tuberculosis Programme, who will present and respond to questions live!
This webinar is our humble tribute to India's pioneer HIV researcher Dr Suniti Solomon who had documented first HIV case in the country and made seminal contribution in fighting AIDS on the ground as well. She left for her heavenly abode recently. Her legacy continues to serve the cause, and inspire us. Read what she said to CNS over the recent years, here.
Date: Tuesday, 25th August 2015
Time: 1:00pm Central European Time, 7:00am Eastern Standard Time, 4:30pm Indian Standard Time
(check www.timeanddate.com for your local time)
Duration: 60 minutes
Language: English (Hindi (हिंदी) summary will be provided at: 6pm-6:30pm IST)
To register, click here
Why join?
Results of few important studies have come very recently, producing strong evidence to improve treatment outcomes for people with TB-HIV co-infection. For example:
Dr Suniti Solomon |
This webinar is our humble tribute to India's pioneer HIV researcher Dr Suniti Solomon who had documented first HIV case in the country and made seminal contribution in fighting AIDS on the ground as well. She left for her heavenly abode recently. Her legacy continues to serve the cause, and inspire us. Read what she said to CNS over the recent years, here.
Date: Tuesday, 25th August 2015
Time: 1:00pm Central European Time, 7:00am Eastern Standard Time, 4:30pm Indian Standard Time
(check www.timeanddate.com for your local time)
Duration: 60 minutes
Language: English (Hindi (हिंदी) summary will be provided at: 6pm-6:30pm IST)
To register, click here
Why join?
Results of few important studies have come very recently, producing strong evidence to improve treatment outcomes for people with TB-HIV co-infection. For example:
- START study was the largest randomized controlled trial ever to see effect of early initiation of antiretroviral therapy (ART). It provided strong evidence that early treatment reduced the risk of the combination of serious AIDS-related illness, serious non-AIDS-related illness and death by more than half compared to deferring treatment. Early treatment reduced the risk of serious AIDS-related and non-AIDS-related illnesses, but had a greater effect on reducing the risk of AIDS-related illnesses. The most common AIDS-related illnesses among study participants were pulmonary tuberculosis, Kaposi’s sarcoma, and non-Hodgkins lymphoma.
- Study: A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa, published in the New England Journal of Medicine (20 July 2015)
- Study called for urgent action to integrate anti-smoking strategies into TB, HIV and TB-HIV care published in the International Journal of Tuberculosis and Lung Disease (10 August 2015)
About the Experts:
- Moderator: Ashok Ramsarup, noted award-winning commentator and senior radio programme producer, South African Broadcasting Corporation (SABC)
- Co-moderator: Shobha Shukla, Managing Editor, CNS
- [Presentation] Dr N Kumarasamy, Chief of Chennai Antiviral Research and Treatment (CART) Clinical Research Site/ NIH Principal Investigator (Chennai) for START trial, and CMO, YRGCARE
- Expert from the International Union Against Tuberculosis and Lung Disease (The Union)
- [Presentation] Dr Avinash Kanchar, Medical Officer, TB/HIV and Community Engagement Unit, Global TB Programme of the World Health Organization (WHO), Geneva
We look forward to hearing your voices and questions in this discussion. And, as always, please email us at webinar@citizen-news.org with questions, comments and suggestions.
Citizen News Service (CNS) Webinars team
Email: webinar@citizen-news.org
Email: webinar@citizen-news.org